Revolution Medicines, Inc.
RVMD
Rang in aandelen
#579
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aandeelprijs
$196.16
Marktkapitalisatie
$42.04B
Verandering (1 dag)
7.69%
Verandering (1 jaar)
263.19%
Land
US
Handel Revolution Medicines, Inc. (RVMD)
Categorie
Healthcare
Winst voor Revolution Medicines, Inc. (RVMD)
Winst in Jun 2026 TTM: $-1.77B
Volgens de meest recente financiële verslagen van Revolution Medicines, Inc. bedraagt de huidige winst van het bedrijf $-1.77B. In 2023 behaalde het bedrijf een winst van $-439.89M, een daling ten opzichte van de winst van 2022, die $-249.13M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Revolution Medicines, Inc. van 2017 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-1.77B | 194.30% |
| 2024 | $-600.85M | 36.59% |
| 2023 | $-439.89M | 76.57% |
| 2022 | $-249.13M | 33.16% |
| 2021 | $-187.09M | 72.39% |
| 2020 | $-108.53M | 108.56% |
| 2019 | $-52.04M | 24.52% |
| 2018 | $-41.79M | 34.25% |
| 2017 | $-31.13M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -398.31% |
US
|
|
| $-3.09B | 74.58% |
US
|
|
| $-4.02B | 127.12% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -210.31% |
NL
|
